nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—BTK—Mitoxantrone—sarcoma	0.145	0.524	CbGbCtD
Dasatinib—PDGFRB—sarcoma	0.125	0.286	CbGaD
Dasatinib—PDGFRA—sarcoma	0.122	0.279	CbGaD
Dasatinib—SRC—sarcoma	0.101	0.231	CbGaD
Dasatinib—KIT—sarcoma	0.0895	0.205	CbGaD
Dasatinib—CYP1B1—Mitoxantrone—sarcoma	0.023	0.083	CbGbCtD
Dasatinib—CYP1A1—Dacarbazine—sarcoma	0.013	0.0469	CbGbCtD
Dasatinib—ABCG2—Dactinomycin—sarcoma	0.0122	0.0441	CbGbCtD
Dasatinib—ABCG2—Mitoxantrone—sarcoma	0.011	0.0394	CbGbCtD
Dasatinib—CYP1B1—Doxorubicin—sarcoma	0.00991	0.0357	CbGbCtD
Dasatinib—ABCG2—Vincristine—sarcoma	0.00754	0.0271	CbGbCtD
Dasatinib—ABCG2—Etoposide—sarcoma	0.00691	0.0249	CbGbCtD
Dasatinib—CYP1A2—Dacarbazine—sarcoma	0.00582	0.021	CbGbCtD
Dasatinib—CYP3A4—Thiotepa—sarcoma	0.0055	0.0198	CbGbCtD
Dasatinib—ABCG2—Doxorubicin—sarcoma	0.00471	0.017	CbGbCtD
Dasatinib—ABCB1—Dactinomycin—sarcoma	0.00441	0.0159	CbGbCtD
Dasatinib—CYP3A5—Vincristine—sarcoma	0.00418	0.015	CbGbCtD
Dasatinib—ABCB1—Mitoxantrone—sarcoma	0.00395	0.0142	CbGbCtD
Dasatinib—CYP3A5—Etoposide—sarcoma	0.00383	0.0138	CbGbCtD
Dasatinib—CYP1A2—Etoposide—sarcoma	0.00285	0.0103	CbGbCtD
Dasatinib—ABCB1—Vincristine—sarcoma	0.00272	0.00979	CbGbCtD
Dasatinib—ABCB1—Etoposide—sarcoma	0.00249	0.00897	CbGbCtD
Dasatinib—CYP3A4—Mitoxantrone—sarcoma	0.00237	0.00852	CbGbCtD
Dasatinib—ABCB1—Doxorubicin—sarcoma	0.0017	0.00612	CbGbCtD
Dasatinib—CYP3A4—Vincristine—sarcoma	0.00163	0.00586	CbGbCtD
Dasatinib—CYP3A4—Etoposide—sarcoma	0.00149	0.00537	CbGbCtD
Dasatinib—CYP3A4—Doxorubicin—sarcoma	0.00102	0.00367	CbGbCtD
Dasatinib—ERBB3—Podofilox—Etoposide—sarcoma	0.00037	0.182	CbGdCrCtD
Dasatinib—ERBB3—Vinblastine—Vincristine—sarcoma	0.000255	0.126	CbGdCrCtD
Dasatinib—CSK—Doxorubicin—Epirubicin—sarcoma	0.000178	0.0878	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Epirubicin—sarcoma	0.000178	0.0878	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Doxorubicin—sarcoma	0.000165	0.0812	CbGdCrCtD
Dasatinib—CSK—Epirubicin—Doxorubicin—sarcoma	0.000165	0.0812	CbGdCrCtD
Dasatinib—SIK1—lymphoid tissue—sarcoma	0.000136	0.00179	CbGeAlD
Dasatinib—TNK2—testis—sarcoma	0.000135	0.00179	CbGeAlD
Dasatinib—KIT—myometrium—sarcoma	0.000134	0.00178	CbGeAlD
Dasatinib—HCK—bone marrow—sarcoma	0.000134	0.00178	CbGeAlD
Dasatinib—CSF1R—seminal vesicle—sarcoma	0.000134	0.00177	CbGeAlD
Dasatinib—TXK—lymph node—sarcoma	0.000133	0.00176	CbGeAlD
Dasatinib—ERBB3—lymphoid tissue—sarcoma	0.000133	0.00176	CbGeAlD
Dasatinib—MAPK14—uterus—sarcoma	0.000133	0.00175	CbGeAlD
Dasatinib—EPHB6—skin of body—sarcoma	0.000132	0.00175	CbGeAlD
Dasatinib—LYN—liver—sarcoma	0.000132	0.00175	CbGeAlD
Dasatinib—LCK—uterus—sarcoma	0.000132	0.00175	CbGeAlD
Dasatinib—MAP3K2—lymphoid tissue—sarcoma	0.000132	0.00174	CbGeAlD
Dasatinib—PDGFRB—myometrium—sarcoma	0.000131	0.00174	CbGeAlD
Dasatinib—RIPK2—tendon—sarcoma	0.00013	0.00172	CbGeAlD
Dasatinib—YES1—smooth muscle tissue—sarcoma	0.00013	0.00171	CbGeAlD
Dasatinib—BTK—liver—sarcoma	0.00013	0.00171	CbGeAlD
Dasatinib—KIT—embryo—sarcoma	0.000129	0.00171	CbGeAlD
Dasatinib—TNK2—liver—sarcoma	0.000128	0.00169	CbGeAlD
Dasatinib—SIK1—tendon—sarcoma	0.000127	0.00168	CbGeAlD
Dasatinib—PDGFRA—smooth muscle tissue—sarcoma	0.000127	0.00168	CbGeAlD
Dasatinib—CSF1R—hematopoietic system—sarcoma	0.000127	0.00168	CbGeAlD
Dasatinib—TESK1—testis—sarcoma	0.000127	0.00168	CbGeAlD
Dasatinib—EPHB4—cardiac atrium—sarcoma	0.000126	0.00167	CbGeAlD
Dasatinib—RIPK2—bone marrow—sarcoma	0.000126	0.00167	CbGeAlD
Dasatinib—PDGFRB—embryo—sarcoma	0.000126	0.00167	CbGeAlD
Dasatinib—EPHA4—tendon—sarcoma	0.000126	0.00167	CbGeAlD
Dasatinib—EPHB4—uterus—sarcoma	0.000126	0.00166	CbGeAlD
Dasatinib—JAK2—cardiac atrium—sarcoma	0.000126	0.00166	CbGeAlD
Dasatinib—STK36—testis—sarcoma	0.000125	0.00165	CbGeAlD
Dasatinib—EPHB3—testis—sarcoma	0.000125	0.00165	CbGeAlD
Dasatinib—SRC—smooth muscle tissue—sarcoma	0.000125	0.00165	CbGeAlD
Dasatinib—STAT5B—lymph node—sarcoma	0.000125	0.00165	CbGeAlD
Dasatinib—ABL1—Idarubicin—Epirubicin—sarcoma	0.000125	0.0613	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Epirubicin—sarcoma	0.000125	0.0613	CbGdCrCtD
Dasatinib—ABL1—Doxorubicin—Epirubicin—sarcoma	0.000125	0.0613	CbGdCrCtD
Dasatinib—EPHA2—cardiac atrium—sarcoma	0.000124	0.00164	CbGeAlD
Dasatinib—FYN—cardiac atrium—sarcoma	0.000124	0.00164	CbGeAlD
Dasatinib—MAPK14—lymphoid tissue—sarcoma	0.000124	0.00164	CbGeAlD
Dasatinib—SIK1—bone marrow—sarcoma	0.000123	0.00163	CbGeAlD
Dasatinib—FYN—uterus—sarcoma	0.000123	0.00163	CbGeAlD
Dasatinib—FGR—lymphoid tissue—sarcoma	0.000123	0.00163	CbGeAlD
Dasatinib—SRC—skin of body—sarcoma	0.000123	0.00163	CbGeAlD
Dasatinib—CSF1R—connective tissue—sarcoma	0.000122	0.00162	CbGeAlD
Dasatinib—KIT—seminal vesicle—sarcoma	0.000121	0.00161	CbGeAlD
Dasatinib—MAP3K3—cardiac atrium—sarcoma	0.000121	0.0016	CbGeAlD
Dasatinib—MAP4K5—cardiac atrium—sarcoma	0.000121	0.0016	CbGeAlD
Dasatinib—LIMK2—testis—sarcoma	0.000121	0.0016	CbGeAlD
Dasatinib—MAP4K5—uterus—sarcoma	0.00012	0.00159	CbGeAlD
Dasatinib—TESK1—liver—sarcoma	0.00012	0.00159	CbGeAlD
Dasatinib—MAP3K2—bone marrow—sarcoma	0.00012	0.00158	CbGeAlD
Dasatinib—PDGFRB—seminal vesicle—sarcoma	0.000119	0.00157	CbGeAlD
Dasatinib—STK36—liver—sarcoma	0.000118	0.00156	CbGeAlD
Dasatinib—STK35—testis—sarcoma	0.000117	0.00155	CbGeAlD
Dasatinib—ABL1—myometrium—sarcoma	0.000117	0.00155	CbGeAlD
Dasatinib—JAK2—lymphoid tissue—sarcoma	0.000116	0.00154	CbGeAlD
Dasatinib—CSK—testis—sarcoma	0.000116	0.00154	CbGeAlD
Dasatinib—MAPK14—tendon—sarcoma	0.000116	0.00154	CbGeAlD
Dasatinib—FGR—tendon—sarcoma	0.000116	0.00153	CbGeAlD
Dasatinib—EPHB6—cardiac atrium—sarcoma	0.000116	0.00153	CbGeAlD
Dasatinib—KIT—hematopoietic system—sarcoma	0.000115	0.00153	CbGeAlD
Dasatinib—EPHA3—lymph node—sarcoma	0.000115	0.00152	CbGeAlD
Dasatinib—ABL1—Daunorubicin—Doxorubicin—sarcoma	0.000115	0.0567	CbGdCrCtD
Dasatinib—ABL1—Epirubicin—Doxorubicin—sarcoma	0.000115	0.0567	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Doxorubicin—sarcoma	0.000115	0.0567	CbGdCrCtD
Dasatinib—EPHA2—lymphoid tissue—sarcoma	0.000115	0.00152	CbGeAlD
Dasatinib—HCK—testis—sarcoma	0.000115	0.00152	CbGeAlD
Dasatinib—FYN—lymphoid tissue—sarcoma	0.000115	0.00152	CbGeAlD
Dasatinib—LIMK2—liver—sarcoma	0.000114	0.00151	CbGeAlD
Dasatinib—ABL2—testis—sarcoma	0.000114	0.00151	CbGeAlD
Dasatinib—PDGFRB—hematopoietic system—sarcoma	0.000113	0.00149	CbGeAlD
Dasatinib—MAPK14—bone marrow—sarcoma	0.000113	0.00149	CbGeAlD
Dasatinib—ABL1—embryo—sarcoma	0.000113	0.00149	CbGeAlD
Dasatinib—MAP4K5—lymphoid tissue—sarcoma	0.000112	0.00148	CbGeAlD
Dasatinib—FGR—bone marrow—sarcoma	0.000112	0.00148	CbGeAlD
Dasatinib—LCK—bone marrow—sarcoma	0.000112	0.00148	CbGeAlD
Dasatinib—SIK3—lymph node—sarcoma	0.000112	0.00148	CbGeAlD
Dasatinib—CSF1R—smooth muscle tissue—sarcoma	0.000112	0.00148	CbGeAlD
Dasatinib—YES1—cardiac atrium—sarcoma	0.000112	0.00148	CbGeAlD
Dasatinib—YES1—uterus—sarcoma	0.000111	0.00147	CbGeAlD
Dasatinib—KIT—connective tissue—sarcoma	0.000111	0.00147	CbGeAlD
Dasatinib—STK35—liver—sarcoma	0.000111	0.00146	CbGeAlD
Dasatinib—CSF1R—skin of body—sarcoma	0.000111	0.00146	CbGeAlD
Dasatinib—EPHB4—tendon—sarcoma	0.00011	0.00146	CbGeAlD
Dasatinib—CSK—liver—sarcoma	0.00011	0.00145	CbGeAlD
Dasatinib—JAK2—tendon—sarcoma	0.000109	0.00145	CbGeAlD
Dasatinib—PDGFRA—uterus—sarcoma	0.000109	0.00144	CbGeAlD
Dasatinib—HCK—liver—sarcoma	0.000109	0.00144	CbGeAlD
Dasatinib—PDGFRB—connective tissue—sarcoma	0.000109	0.00144	CbGeAlD
Dasatinib—EPHA2—tendon—sarcoma	0.000108	0.00143	CbGeAlD
Dasatinib—RIPK2—testis—sarcoma	0.000108	0.00143	CbGeAlD
Dasatinib—FYN—tendon—sarcoma	0.000108	0.00143	CbGeAlD
Dasatinib—ABL2—liver—sarcoma	0.000108	0.00143	CbGeAlD
Dasatinib—SRC—cardiac atrium—sarcoma	0.000108	0.00142	CbGeAlD
Dasatinib—EPHB4—bone marrow—sarcoma	0.000107	0.00141	CbGeAlD
Dasatinib—JAK2—bone marrow—sarcoma	0.000106	0.0014	CbGeAlD
Dasatinib—ABL1—seminal vesicle—sarcoma	0.000106	0.0014	CbGeAlD
Dasatinib—MAP3K3—tendon—sarcoma	0.000106	0.00139	CbGeAlD
Dasatinib—MAP4K5—tendon—sarcoma	0.000106	0.00139	CbGeAlD
Dasatinib—SIK1—testis—sarcoma	0.000106	0.00139	CbGeAlD
Dasatinib—FYN—bone marrow—sarcoma	0.000105	0.00138	CbGeAlD
Dasatinib—EPHA4—testis—sarcoma	0.000104	0.00138	CbGeAlD
Dasatinib—ZAK—lymph node—sarcoma	0.000104	0.00138	CbGeAlD
Dasatinib—YES1—lymphoid tissue—sarcoma	0.000104	0.00137	CbGeAlD
Dasatinib—ERBB3—testis—sarcoma	0.000103	0.00137	CbGeAlD
Dasatinib—MAP3K2—testis—sarcoma	0.000102	0.00135	CbGeAlD
Dasatinib—MAP4K5—bone marrow—sarcoma	0.000102	0.00135	CbGeAlD
Dasatinib—MAP3K3—bone marrow—sarcoma	0.000102	0.00135	CbGeAlD
Dasatinib—RIPK2—liver—sarcoma	0.000102	0.00135	CbGeAlD
Dasatinib—KIT—smooth muscle tissue—sarcoma	0.000102	0.00134	CbGeAlD
Dasatinib—PDGFRA—lymphoid tissue—sarcoma	0.000102	0.00134	CbGeAlD
Dasatinib—EPHB6—tendon—sarcoma	0.000101	0.00133	CbGeAlD
Dasatinib—ABL1—hematopoietic system—sarcoma	0.000101	0.00133	CbGeAlD
Dasatinib—KIT—skin of body—sarcoma	0.0001	0.00133	CbGeAlD
Dasatinib—BMPR1B—lymph node—sarcoma	9.99e-05	0.00132	CbGeAlD
Dasatinib—SIK1—liver—sarcoma	9.97e-05	0.00132	CbGeAlD
Dasatinib—SRC—lymphoid tissue—sarcoma	9.97e-05	0.00132	CbGeAlD
Dasatinib—BTK—lymph node—sarcoma	9.94e-05	0.00131	CbGeAlD
Dasatinib—PDGFRB—smooth muscle tissue—sarcoma	9.93e-05	0.00131	CbGeAlD
Dasatinib—MAP2K5—cardiac atrium—sarcoma	9.89e-05	0.00131	CbGeAlD
Dasatinib—PDGFRB—skin of body—sarcoma	9.81e-05	0.0013	CbGeAlD
Dasatinib—TNK2—lymph node—sarcoma	9.8e-05	0.00129	CbGeAlD
Dasatinib—ERBB3—liver—sarcoma	9.78e-05	0.00129	CbGeAlD
Dasatinib—YES1—tendon—sarcoma	9.74e-05	0.00129	CbGeAlD
Dasatinib—MAP3K2—liver—sarcoma	9.68e-05	0.00128	CbGeAlD
Dasatinib—ABL1—connective tissue—sarcoma	9.68e-05	0.00128	CbGeAlD
Dasatinib—CSF1R—cardiac atrium—sarcoma	9.66e-05	0.00128	CbGeAlD
Dasatinib—MAPK14—testis—sarcoma	9.63e-05	0.00127	CbGeAlD
Dasatinib—CSF1R—uterus—sarcoma	9.61e-05	0.00127	CbGeAlD
Dasatinib—FGR—testis—sarcoma	9.59e-05	0.00127	CbGeAlD
Dasatinib—LCK—testis—sarcoma	9.59e-05	0.00127	CbGeAlD
Dasatinib—PDGFRA—tendon—sarcoma	9.56e-05	0.00126	CbGeAlD
Dasatinib—YES1—bone marrow—sarcoma	9.44e-05	0.00125	CbGeAlD
Dasatinib—FMO3—testis—sarcoma	9.26e-05	0.00122	CbGeAlD
Dasatinib—TESK1—lymph node—sarcoma	9.21e-05	0.00122	CbGeAlD
Dasatinib—EPHB4—testis—sarcoma	9.13e-05	0.00121	CbGeAlD
Dasatinib—MAPK14—liver—sarcoma	9.1e-05	0.0012	CbGeAlD
Dasatinib—LCK—liver—sarcoma	9.07e-05	0.0012	CbGeAlD
Dasatinib—FGR—liver—sarcoma	9.07e-05	0.0012	CbGeAlD
Dasatinib—JAK2—testis—sarcoma	9.06e-05	0.0012	CbGeAlD
Dasatinib—EPHB3—lymph node—sarcoma	9.06e-05	0.0012	CbGeAlD
Dasatinib—STK36—lymph node—sarcoma	9.06e-05	0.0012	CbGeAlD
Dasatinib—EPHA2—testis—sarcoma	8.96e-05	0.00118	CbGeAlD
Dasatinib—CSF1R—lymphoid tissue—sarcoma	8.95e-05	0.00118	CbGeAlD
Dasatinib—FYN—testis—sarcoma	8.94e-05	0.00118	CbGeAlD
Dasatinib—ABL1—smooth muscle tissue—sarcoma	8.85e-05	0.00117	CbGeAlD
Dasatinib—LIMK2—lymph node—sarcoma	8.76e-05	0.00116	CbGeAlD
Dasatinib—FMO3—liver—sarcoma	8.76e-05	0.00116	CbGeAlD
Dasatinib—ABL1—skin of body—sarcoma	8.74e-05	0.00116	CbGeAlD
Dasatinib—MAP4K5—testis—sarcoma	8.74e-05	0.00115	CbGeAlD
Dasatinib—MAP3K3—testis—sarcoma	8.74e-05	0.00115	CbGeAlD
Dasatinib—KIT—uterus—sarcoma	8.72e-05	0.00115	CbGeAlD
Dasatinib—EPHB4—liver—sarcoma	8.63e-05	0.00114	CbGeAlD
Dasatinib—MAP2K5—tendon—sarcoma	8.62e-05	0.00114	CbGeAlD
Dasatinib—JAK2—liver—sarcoma	8.57e-05	0.00113	CbGeAlD
Dasatinib—PDGFRB—cardiac atrium—sarcoma	8.56e-05	0.00113	CbGeAlD
Dasatinib—PDGFRB—uterus—sarcoma	8.52e-05	0.00113	CbGeAlD
Dasatinib—CYP1B1—hematopoietic system—sarcoma	8.51e-05	0.00113	CbGeAlD
Dasatinib—STK35—lymph node—sarcoma	8.49e-05	0.00112	CbGeAlD
Dasatinib—EPHA2—liver—sarcoma	8.47e-05	0.00112	CbGeAlD
Dasatinib—FYN—liver—sarcoma	8.45e-05	0.00112	CbGeAlD
Dasatinib—CSK—lymph node—sarcoma	8.44e-05	0.00112	CbGeAlD
Dasatinib—CSF1R—tendon—sarcoma	8.42e-05	0.00111	CbGeAlD
Dasatinib—EPHB6—testis—sarcoma	8.35e-05	0.0011	CbGeAlD
Dasatinib—HCK—lymph node—sarcoma	8.33e-05	0.0011	CbGeAlD
Dasatinib—ABL2—lymph node—sarcoma	8.28e-05	0.00109	CbGeAlD
Dasatinib—MAP4K5—liver—sarcoma	8.26e-05	0.00109	CbGeAlD
Dasatinib—MAP3K3—liver—sarcoma	8.26e-05	0.00109	CbGeAlD
Dasatinib—CYP1B1—connective tissue—sarcoma	8.2e-05	0.00108	CbGeAlD
Dasatinib—CSF1R—bone marrow—sarcoma	8.15e-05	0.00108	CbGeAlD
Dasatinib—KIT—lymphoid tissue—sarcoma	8.13e-05	0.00107	CbGeAlD
Dasatinib—YES1—testis—sarcoma	8.07e-05	0.00107	CbGeAlD
Dasatinib—PDGFRB—lymphoid tissue—sarcoma	7.94e-05	0.00105	CbGeAlD
Dasatinib—PDGFRA—testis—sarcoma	7.92e-05	0.00105	CbGeAlD
Dasatinib—RIPK2—lymph node—sarcoma	7.83e-05	0.00104	CbGeAlD
Dasatinib—SRC—testis—sarcoma	7.76e-05	0.00103	CbGeAlD
Dasatinib—SIK1—lymph node—sarcoma	7.65e-05	0.00101	CbGeAlD
Dasatinib—ABL1—cardiac atrium—sarcoma	7.63e-05	0.00101	CbGeAlD
Dasatinib—YES1—liver—sarcoma	7.63e-05	0.00101	CbGeAlD
Dasatinib—ABL1—uterus—sarcoma	7.59e-05	0.001	CbGeAlD
Dasatinib—EPHA4—lymph node—sarcoma	7.57e-05	0.001	CbGeAlD
Dasatinib—CYP1B1—smooth muscle tissue—sarcoma	7.5e-05	0.000991	CbGeAlD
Dasatinib—ERBB3—lymph node—sarcoma	7.5e-05	0.000991	CbGeAlD
Dasatinib—PDGFRA—liver—sarcoma	7.48e-05	0.000989	CbGeAlD
Dasatinib—PDGFRB—tendon—sarcoma	7.46e-05	0.000987	CbGeAlD
Dasatinib—MAP3K2—lymph node—sarcoma	7.42e-05	0.000981	CbGeAlD
Dasatinib—KIT—bone marrow—sarcoma	7.4e-05	0.000978	CbGeAlD
Dasatinib—CYP1B1—skin of body—sarcoma	7.4e-05	0.000978	CbGeAlD
Dasatinib—ABCG2—myometrium—sarcoma	7.38e-05	0.000976	CbGeAlD
Dasatinib—SRC—liver—sarcoma	7.34e-05	0.00097	CbGeAlD
Dasatinib—PDGFRB—bone marrow—sarcoma	7.23e-05	0.000956	CbGeAlD
Dasatinib—MAP2K5—testis—sarcoma	7.14e-05	0.000944	CbGeAlD
Dasatinib—ABL1—lymphoid tissue—sarcoma	7.08e-05	0.000935	CbGeAlD
Dasatinib—MAPK14—lymph node—sarcoma	6.98e-05	0.000923	CbGeAlD
Dasatinib—CSF1R—testis—sarcoma	6.97e-05	0.000921	CbGeAlD
Dasatinib—FGR—lymph node—sarcoma	6.95e-05	0.000919	CbGeAlD
Dasatinib—LCK—lymph node—sarcoma	6.95e-05	0.000919	CbGeAlD
Dasatinib—MAP2K5—liver—sarcoma	6.75e-05	0.000892	CbGeAlD
Dasatinib—FMO3—lymph node—sarcoma	6.71e-05	0.000887	CbGeAlD
Dasatinib—ABCG2—seminal vesicle—sarcoma	6.67e-05	0.000882	CbGeAlD
Dasatinib—ABL1—tendon—sarcoma	6.65e-05	0.000879	CbGeAlD
Dasatinib—EPHB4—lymph node—sarcoma	6.62e-05	0.000875	CbGeAlD
Dasatinib—CSF1R—liver—sarcoma	6.59e-05	0.000871	CbGeAlD
Dasatinib—JAK2—lymph node—sarcoma	6.57e-05	0.000869	CbGeAlD
Dasatinib—EPHA2—lymph node—sarcoma	6.49e-05	0.000858	CbGeAlD
Dasatinib—FYN—lymph node—sarcoma	6.48e-05	0.000857	CbGeAlD
Dasatinib—ABL1—bone marrow—sarcoma	6.44e-05	0.000852	CbGeAlD
Dasatinib—CYP1B1—uterus—sarcoma	6.43e-05	0.00085	CbGeAlD
Dasatinib—MAP4K5—lymph node—sarcoma	6.33e-05	0.000837	CbGeAlD
Dasatinib—MAP3K3—lymph node—sarcoma	6.33e-05	0.000837	CbGeAlD
Dasatinib—KIT—testis—sarcoma	6.33e-05	0.000836	CbGeAlD
Dasatinib—PDGFRB—testis—sarcoma	6.18e-05	0.000817	CbGeAlD
Dasatinib—CYP1A2—hematopoietic system—sarcoma	6.1e-05	0.000806	CbGeAlD
Dasatinib—EPHB6—lymph node—sarcoma	6.05e-05	0.0008	CbGeAlD
Dasatinib—CYP1A1—hematopoietic system—sarcoma	6.02e-05	0.000795	CbGeAlD
Dasatinib—CYP1B1—lymphoid tissue—sarcoma	5.99e-05	0.000792	CbGeAlD
Dasatinib—KIT—liver—sarcoma	5.98e-05	0.000791	CbGeAlD
Dasatinib—CYP3A5—hematopoietic system—sarcoma	5.88e-05	0.000778	CbGeAlD
Dasatinib—YES1—lymph node—sarcoma	5.85e-05	0.000773	CbGeAlD
Dasatinib—PDGFRB—liver—sarcoma	5.84e-05	0.000772	CbGeAlD
Dasatinib—PDGFRA—lymph node—sarcoma	5.74e-05	0.000758	CbGeAlD
Dasatinib—CYP1B1—tendon—sarcoma	5.63e-05	0.000745	CbGeAlD
Dasatinib—Diarrhoea—Thiotepa—sarcoma	5.63e-05	0.000676	CcSEcCtD
Dasatinib—SRC—lymph node—sarcoma	5.63e-05	0.000744	CbGeAlD
Dasatinib—Body temperature increased—Mitoxantrone—sarcoma	5.62e-05	0.000675	CcSEcCtD
Dasatinib—Abdominal pain—Mitoxantrone—sarcoma	5.62e-05	0.000675	CcSEcCtD
Dasatinib—Aspartate aminotransferase increased—Doxorubicin—sarcoma	5.62e-05	0.000675	CcSEcCtD
Dasatinib—Diarrhoea—Dactinomycin—sarcoma	5.59e-05	0.000671	CcSEcCtD
Dasatinib—Pancytopenia—Epirubicin—sarcoma	5.54e-05	0.000665	CcSEcCtD
Dasatinib—Hypotension—Etoposide—sarcoma	5.53e-05	0.000663	CcSEcCtD
Dasatinib—Gastritis—Doxorubicin—sarcoma	5.52e-05	0.000663	CcSEcCtD
Dasatinib—ABL1—testis—sarcoma	5.51e-05	0.000728	CbGeAlD
Dasatinib—Muscular weakness—Doxorubicin—sarcoma	5.5e-05	0.000661	CcSEcCtD
Dasatinib—Alanine aminotransferase increased—Doxorubicin—sarcoma	5.5e-05	0.000661	CcSEcCtD
Dasatinib—Neutropenia—Epirubicin—sarcoma	5.45e-05	0.000654	CcSEcCtD
Dasatinib—Dizziness—Thiotepa—sarcoma	5.44e-05	0.000654	CcSEcCtD
Dasatinib—Abdominal distension—Doxorubicin—sarcoma	5.43e-05	0.000652	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Epirubicin—sarcoma	5.42e-05	0.00065	CcSEcCtD
Dasatinib—Asthma—Doxorubicin—sarcoma	5.39e-05	0.000648	CcSEcCtD
Dasatinib—Dysphagia—Doxorubicin—sarcoma	5.39e-05	0.000648	CcSEcCtD
Dasatinib—Pollakiuria—Epirubicin—sarcoma	5.39e-05	0.000647	CcSEcCtD
Dasatinib—Hypersensitivity—Vincristine—sarcoma	5.38e-05	0.000646	CcSEcCtD
Dasatinib—Photosensitivity reaction—Epirubicin—sarcoma	5.32e-05	0.000639	CcSEcCtD
Dasatinib—Weight increased—Epirubicin—sarcoma	5.31e-05	0.000637	CcSEcCtD
Dasatinib—Pancreatitis—Doxorubicin—sarcoma	5.29e-05	0.000635	CcSEcCtD
Dasatinib—Weight decreased—Epirubicin—sarcoma	5.27e-05	0.000633	CcSEcCtD
Dasatinib—Dyspnoea—Etoposide—sarcoma	5.27e-05	0.000633	CcSEcCtD
Dasatinib—Somnolence—Etoposide—sarcoma	5.26e-05	0.000631	CcSEcCtD
Dasatinib—Angina pectoris—Doxorubicin—sarcoma	5.25e-05	0.000631	CcSEcCtD
Dasatinib—Hypersensitivity—Mitoxantrone—sarcoma	5.24e-05	0.000629	CcSEcCtD
Dasatinib—Asthenia—Vincristine—sarcoma	5.24e-05	0.000629	CcSEcCtD
Dasatinib—Vomiting—Thiotepa—sarcoma	5.24e-05	0.000628	CcSEcCtD
Dasatinib—CYP1A1—skin of body—sarcoma	5.23e-05	0.000692	CbGeAlD
Dasatinib—Pneumonia—Epirubicin—sarcoma	5.23e-05	0.000628	CcSEcCtD
Dasatinib—ABL1—liver—sarcoma	5.21e-05	0.000688	CbGeAlD
Dasatinib—Infestation NOS—Epirubicin—sarcoma	5.2e-05	0.000624	CcSEcCtD
Dasatinib—Infestation—Epirubicin—sarcoma	5.2e-05	0.000624	CcSEcCtD
Dasatinib—Vomiting—Dactinomycin—sarcoma	5.2e-05	0.000624	CcSEcCtD
Dasatinib—Rash—Thiotepa—sarcoma	5.19e-05	0.000623	CcSEcCtD
Dasatinib—Dermatitis—Thiotepa—sarcoma	5.19e-05	0.000623	CcSEcCtD
Dasatinib—MAP2K5—lymph node—sarcoma	5.18e-05	0.000684	CbGeAlD
Dasatinib—Headache—Thiotepa—sarcoma	5.16e-05	0.000619	CcSEcCtD
Dasatinib—Rash—Dactinomycin—sarcoma	5.15e-05	0.000619	CcSEcCtD
Dasatinib—Decreased appetite—Etoposide—sarcoma	5.14e-05	0.000617	CcSEcCtD
Dasatinib—Pancytopenia—Doxorubicin—sarcoma	5.12e-05	0.000615	CcSEcCtD
Dasatinib—Renal failure—Epirubicin—sarcoma	5.11e-05	0.000613	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Etoposide—sarcoma	5.11e-05	0.000613	CcSEcCtD
Dasatinib—Asthenia—Mitoxantrone—sarcoma	5.1e-05	0.000612	CcSEcCtD
Dasatinib—Fatigue—Etoposide—sarcoma	5.1e-05	0.000612	CcSEcCtD
Dasatinib—Neuropathy peripheral—Epirubicin—sarcoma	5.1e-05	0.000612	CcSEcCtD
Dasatinib—Stomatitis—Epirubicin—sarcoma	5.07e-05	0.000608	CcSEcCtD
Dasatinib—Pain—Etoposide—sarcoma	5.06e-05	0.000607	CcSEcCtD
Dasatinib—Constipation—Etoposide—sarcoma	5.06e-05	0.000607	CcSEcCtD
Dasatinib—Conjunctivitis—Epirubicin—sarcoma	5.05e-05	0.000607	CcSEcCtD
Dasatinib—CSF1R—lymph node—sarcoma	5.05e-05	0.000668	CbGeAlD
Dasatinib—Neutropenia—Doxorubicin—sarcoma	5.04e-05	0.000606	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Doxorubicin—sarcoma	5.01e-05	0.000602	CcSEcCtD
Dasatinib—Diarrhoea—Vincristine—sarcoma	5e-05	0.0006	CcSEcCtD
Dasatinib—Pollakiuria—Doxorubicin—sarcoma	4.98e-05	0.000598	CcSEcCtD
Dasatinib—Haematuria—Epirubicin—sarcoma	4.96e-05	0.000595	CcSEcCtD
Dasatinib—Photosensitivity reaction—Doxorubicin—sarcoma	4.92e-05	0.000591	CcSEcCtD
Dasatinib—Hepatobiliary disease—Epirubicin—sarcoma	4.92e-05	0.00059	CcSEcCtD
Dasatinib—Weight increased—Doxorubicin—sarcoma	4.91e-05	0.000589	CcSEcCtD
Dasatinib—Epistaxis—Epirubicin—sarcoma	4.9e-05	0.000589	CcSEcCtD
Dasatinib—Nausea—Thiotepa—sarcoma	4.89e-05	0.000587	CcSEcCtD
Dasatinib—Weight decreased—Doxorubicin—sarcoma	4.88e-05	0.000586	CcSEcCtD
Dasatinib—Feeling abnormal—Etoposide—sarcoma	4.87e-05	0.000585	CcSEcCtD
Dasatinib—Diarrhoea—Mitoxantrone—sarcoma	4.87e-05	0.000584	CcSEcCtD
Dasatinib—Nausea—Dactinomycin—sarcoma	4.85e-05	0.000583	CcSEcCtD
Dasatinib—Pneumonia—Doxorubicin—sarcoma	4.84e-05	0.000581	CcSEcCtD
Dasatinib—Gastrointestinal pain—Etoposide—sarcoma	4.84e-05	0.000581	CcSEcCtD
Dasatinib—Dizziness—Vincristine—sarcoma	4.83e-05	0.00058	CcSEcCtD
Dasatinib—Infestation—Doxorubicin—sarcoma	4.81e-05	0.000577	CcSEcCtD
Dasatinib—Infestation NOS—Doxorubicin—sarcoma	4.81e-05	0.000577	CcSEcCtD
Dasatinib—ABCG2—uterus—sarcoma	4.79e-05	0.000633	CbGeAlD
Dasatinib—Renal failure—Doxorubicin—sarcoma	4.73e-05	0.000568	CcSEcCtD
Dasatinib—Neuropathy peripheral—Doxorubicin—sarcoma	4.71e-05	0.000566	CcSEcCtD
Dasatinib—Urticaria—Etoposide—sarcoma	4.7e-05	0.000564	CcSEcCtD
Dasatinib—Haemoglobin—Epirubicin—sarcoma	4.69e-05	0.000563	CcSEcCtD
Dasatinib—Stomatitis—Doxorubicin—sarcoma	4.69e-05	0.000563	CcSEcCtD
Dasatinib—Body temperature increased—Etoposide—sarcoma	4.68e-05	0.000561	CcSEcCtD
Dasatinib—Abdominal pain—Etoposide—sarcoma	4.68e-05	0.000561	CcSEcCtD
Dasatinib—Conjunctivitis—Doxorubicin—sarcoma	4.68e-05	0.000561	CcSEcCtD
Dasatinib—Haemorrhage—Epirubicin—sarcoma	4.67e-05	0.00056	CcSEcCtD
Dasatinib—Hepatitis—Epirubicin—sarcoma	4.67e-05	0.00056	CcSEcCtD
Dasatinib—CYP1B1—testis—sarcoma	4.67e-05	0.000617	CbGeAlD
Dasatinib—Vomiting—Vincristine—sarcoma	4.64e-05	0.000557	CcSEcCtD
Dasatinib—Urinary tract disorder—Epirubicin—sarcoma	4.61e-05	0.000553	CcSEcCtD
Dasatinib—Rash—Vincristine—sarcoma	4.6e-05	0.000553	CcSEcCtD
Dasatinib—Dermatitis—Vincristine—sarcoma	4.6e-05	0.000552	CcSEcCtD
Dasatinib—Oedema peripheral—Epirubicin—sarcoma	4.6e-05	0.000552	CcSEcCtD
Dasatinib—KIT—lymph node—sarcoma	4.59e-05	0.000606	CbGeAlD
Dasatinib—Haematuria—Doxorubicin—sarcoma	4.59e-05	0.000551	CcSEcCtD
Dasatinib—Connective tissue disorder—Epirubicin—sarcoma	4.59e-05	0.000551	CcSEcCtD
Dasatinib—Urethral disorder—Epirubicin—sarcoma	4.57e-05	0.000549	CcSEcCtD
Dasatinib—Headache—Vincristine—sarcoma	4.57e-05	0.000549	CcSEcCtD
Dasatinib—CYP1A1—cardiac atrium—sarcoma	4.57e-05	0.000604	CbGeAlD
Dasatinib—Hepatobiliary disease—Doxorubicin—sarcoma	4.55e-05	0.000546	CcSEcCtD
Dasatinib—CYP1A1—uterus—sarcoma	4.55e-05	0.000601	CbGeAlD
Dasatinib—Epistaxis—Doxorubicin—sarcoma	4.54e-05	0.000545	CcSEcCtD
Dasatinib—Vomiting—Mitoxantrone—sarcoma	4.52e-05	0.000543	CcSEcCtD
Dasatinib—Visual impairment—Epirubicin—sarcoma	4.5e-05	0.00054	CcSEcCtD
Dasatinib—Rash—Mitoxantrone—sarcoma	4.48e-05	0.000538	CcSEcCtD
Dasatinib—PDGFRB—lymph node—sarcoma	4.48e-05	0.000592	CbGeAlD
Dasatinib—Dermatitis—Mitoxantrone—sarcoma	4.48e-05	0.000538	CcSEcCtD
Dasatinib—Headache—Mitoxantrone—sarcoma	4.45e-05	0.000535	CcSEcCtD
Dasatinib—CYP3A4—hematopoietic system—sarcoma	4.42e-05	0.000584	CbGeAlD
Dasatinib—Erythema multiforme—Epirubicin—sarcoma	4.41e-05	0.00053	CcSEcCtD
Dasatinib—CYP1B1—liver—sarcoma	4.41e-05	0.000583	CbGeAlD
Dasatinib—Eye disorder—Epirubicin—sarcoma	4.36e-05	0.000524	CcSEcCtD
Dasatinib—Hypersensitivity—Etoposide—sarcoma	4.36e-05	0.000523	CcSEcCtD
Dasatinib—Tinnitus—Epirubicin—sarcoma	4.35e-05	0.000522	CcSEcCtD
Dasatinib—Haemoglobin—Doxorubicin—sarcoma	4.34e-05	0.000521	CcSEcCtD
Dasatinib—Nausea—Vincristine—sarcoma	4.34e-05	0.000521	CcSEcCtD
Dasatinib—Cardiac disorder—Epirubicin—sarcoma	4.33e-05	0.00052	CcSEcCtD
Dasatinib—Flushing—Epirubicin—sarcoma	4.33e-05	0.00052	CcSEcCtD
Dasatinib—Hepatitis—Doxorubicin—sarcoma	4.32e-05	0.000518	CcSEcCtD
Dasatinib—Haemorrhage—Doxorubicin—sarcoma	4.32e-05	0.000518	CcSEcCtD
Dasatinib—Urinary tract disorder—Doxorubicin—sarcoma	4.26e-05	0.000512	CcSEcCtD
Dasatinib—Oedema peripheral—Doxorubicin—sarcoma	4.25e-05	0.000511	CcSEcCtD
Dasatinib—Asthenia—Etoposide—sarcoma	4.24e-05	0.000509	CcSEcCtD
Dasatinib—Connective tissue disorder—Doxorubicin—sarcoma	4.24e-05	0.000509	CcSEcCtD
Dasatinib—Angiopathy—Epirubicin—sarcoma	4.23e-05	0.000508	CcSEcCtD
Dasatinib—Urethral disorder—Doxorubicin—sarcoma	4.23e-05	0.000508	CcSEcCtD
Dasatinib—Nausea—Mitoxantrone—sarcoma	4.22e-05	0.000507	CcSEcCtD
Dasatinib—Immune system disorder—Epirubicin—sarcoma	4.22e-05	0.000506	CcSEcCtD
Dasatinib—Mediastinal disorder—Epirubicin—sarcoma	4.21e-05	0.000505	CcSEcCtD
Dasatinib—Chills—Epirubicin—sarcoma	4.19e-05	0.000503	CcSEcCtD
Dasatinib—Pruritus—Etoposide—sarcoma	4.18e-05	0.000502	CcSEcCtD
Dasatinib—Arrhythmia—Epirubicin—sarcoma	4.17e-05	0.0005	CcSEcCtD
Dasatinib—Visual impairment—Doxorubicin—sarcoma	4.16e-05	0.0005	CcSEcCtD
Dasatinib—Alopecia—Epirubicin—sarcoma	4.12e-05	0.000495	CcSEcCtD
Dasatinib—Mental disorder—Epirubicin—sarcoma	4.09e-05	0.000491	CcSEcCtD
Dasatinib—Erythema multiforme—Doxorubicin—sarcoma	4.08e-05	0.00049	CcSEcCtD
Dasatinib—ABCG2—bone marrow—sarcoma	4.06e-05	0.000537	CbGeAlD
Dasatinib—Malnutrition—Epirubicin—sarcoma	4.06e-05	0.000488	CcSEcCtD
Dasatinib—Erythema—Epirubicin—sarcoma	4.06e-05	0.000488	CcSEcCtD
Dasatinib—Diarrhoea—Etoposide—sarcoma	4.05e-05	0.000486	CcSEcCtD
Dasatinib—Eye disorder—Doxorubicin—sarcoma	4.04e-05	0.000484	CcSEcCtD
Dasatinib—Tinnitus—Doxorubicin—sarcoma	4.03e-05	0.000483	CcSEcCtD
Dasatinib—Cardiac disorder—Doxorubicin—sarcoma	4.01e-05	0.000481	CcSEcCtD
Dasatinib—Flushing—Doxorubicin—sarcoma	4.01e-05	0.000481	CcSEcCtD
Dasatinib—ABL1—lymph node—sarcoma	3.99e-05	0.000528	CbGeAlD
Dasatinib—Dysgeusia—Epirubicin—sarcoma	3.98e-05	0.000478	CcSEcCtD
Dasatinib—Angiopathy—Doxorubicin—sarcoma	3.92e-05	0.00047	CcSEcCtD
Dasatinib—Dizziness—Etoposide—sarcoma	3.91e-05	0.00047	CcSEcCtD
Dasatinib—Muscle spasms—Epirubicin—sarcoma	3.91e-05	0.000469	CcSEcCtD
Dasatinib—Immune system disorder—Doxorubicin—sarcoma	3.9e-05	0.000468	CcSEcCtD
Dasatinib—Mediastinal disorder—Doxorubicin—sarcoma	3.89e-05	0.000467	CcSEcCtD
Dasatinib—Chills—Doxorubicin—sarcoma	3.87e-05	0.000465	CcSEcCtD
Dasatinib—Arrhythmia—Doxorubicin—sarcoma	3.86e-05	0.000463	CcSEcCtD
Dasatinib—Vision blurred—Epirubicin—sarcoma	3.83e-05	0.00046	CcSEcCtD
Dasatinib—Alopecia—Doxorubicin—sarcoma	3.82e-05	0.000458	CcSEcCtD
Dasatinib—Mental disorder—Doxorubicin—sarcoma	3.78e-05	0.000454	CcSEcCtD
Dasatinib—Ill-defined disorder—Epirubicin—sarcoma	3.77e-05	0.000452	CcSEcCtD
Dasatinib—Vomiting—Etoposide—sarcoma	3.76e-05	0.000451	CcSEcCtD
Dasatinib—Erythema—Doxorubicin—sarcoma	3.76e-05	0.000451	CcSEcCtD
Dasatinib—Malnutrition—Doxorubicin—sarcoma	3.76e-05	0.000451	CcSEcCtD
Dasatinib—Anaemia—Epirubicin—sarcoma	3.75e-05	0.000451	CcSEcCtD
Dasatinib—Rash—Etoposide—sarcoma	3.73e-05	0.000448	CcSEcCtD
Dasatinib—Dermatitis—Etoposide—sarcoma	3.73e-05	0.000447	CcSEcCtD
Dasatinib—Headache—Etoposide—sarcoma	3.71e-05	0.000445	CcSEcCtD
Dasatinib—Dysgeusia—Doxorubicin—sarcoma	3.68e-05	0.000442	CcSEcCtD
Dasatinib—Malaise—Epirubicin—sarcoma	3.66e-05	0.00044	CcSEcCtD
Dasatinib—Vertigo—Epirubicin—sarcoma	3.65e-05	0.000438	CcSEcCtD
Dasatinib—Syncope—Epirubicin—sarcoma	3.64e-05	0.000437	CcSEcCtD
Dasatinib—ABCB1—myometrium—sarcoma	3.64e-05	0.000481	CbGeAlD
Dasatinib—Muscle spasms—Doxorubicin—sarcoma	3.61e-05	0.000434	CcSEcCtD
Dasatinib—Palpitations—Epirubicin—sarcoma	3.59e-05	0.000431	CcSEcCtD
Dasatinib—Loss of consciousness—Epirubicin—sarcoma	3.57e-05	0.000429	CcSEcCtD
Dasatinib—Cough—Epirubicin—sarcoma	3.54e-05	0.000426	CcSEcCtD
Dasatinib—Vision blurred—Doxorubicin—sarcoma	3.54e-05	0.000425	CcSEcCtD
Dasatinib—Convulsion—Epirubicin—sarcoma	3.52e-05	0.000423	CcSEcCtD
Dasatinib—Nausea—Etoposide—sarcoma	3.51e-05	0.000422	CcSEcCtD
Dasatinib—Hypertension—Epirubicin—sarcoma	3.51e-05	0.000421	CcSEcCtD
Dasatinib—ABCB1—embryo—sarcoma	3.5e-05	0.000463	CbGeAlD
Dasatinib—Ill-defined disorder—Doxorubicin—sarcoma	3.49e-05	0.000419	CcSEcCtD
Dasatinib—Anaemia—Doxorubicin—sarcoma	3.47e-05	0.000417	CcSEcCtD
Dasatinib—ABCG2—testis—sarcoma	3.47e-05	0.000459	CbGeAlD
Dasatinib—Myalgia—Epirubicin—sarcoma	3.46e-05	0.000415	CcSEcCtD
Dasatinib—Chest pain—Epirubicin—sarcoma	3.46e-05	0.000415	CcSEcCtD
Dasatinib—Arthralgia—Epirubicin—sarcoma	3.46e-05	0.000415	CcSEcCtD
Dasatinib—Anxiety—Epirubicin—sarcoma	3.45e-05	0.000414	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	3.43e-05	0.000412	CcSEcCtD
Dasatinib—Discomfort—Epirubicin—sarcoma	3.42e-05	0.00041	CcSEcCtD
Dasatinib—Malaise—Doxorubicin—sarcoma	3.39e-05	0.000407	CcSEcCtD
Dasatinib—CYP1B1—lymph node—sarcoma	3.38e-05	0.000447	CbGeAlD
Dasatinib—Vertigo—Doxorubicin—sarcoma	3.38e-05	0.000405	CcSEcCtD
Dasatinib—Syncope—Doxorubicin—sarcoma	3.37e-05	0.000405	CcSEcCtD
Dasatinib—Confusional state—Epirubicin—sarcoma	3.34e-05	0.000401	CcSEcCtD
Dasatinib—Palpitations—Doxorubicin—sarcoma	3.32e-05	0.000399	CcSEcCtD
Dasatinib—Oedema—Epirubicin—sarcoma	3.32e-05	0.000398	CcSEcCtD
Dasatinib—Loss of consciousness—Doxorubicin—sarcoma	3.3e-05	0.000397	CcSEcCtD
Dasatinib—Infection—Epirubicin—sarcoma	3.29e-05	0.000395	CcSEcCtD
Dasatinib—ABCB1—seminal vesicle—sarcoma	3.29e-05	0.000435	CbGeAlD
Dasatinib—ABCG2—liver—sarcoma	3.28e-05	0.000434	CbGeAlD
Dasatinib—Cough—Doxorubicin—sarcoma	3.28e-05	0.000394	CcSEcCtD
Dasatinib—Shock—Epirubicin—sarcoma	3.26e-05	0.000392	CcSEcCtD
Dasatinib—Convulsion—Doxorubicin—sarcoma	3.26e-05	0.000391	CcSEcCtD
Dasatinib—Nervous system disorder—Epirubicin—sarcoma	3.25e-05	0.00039	CcSEcCtD
Dasatinib—Thrombocytopenia—Epirubicin—sarcoma	3.25e-05	0.00039	CcSEcCtD
Dasatinib—Hypertension—Doxorubicin—sarcoma	3.25e-05	0.00039	CcSEcCtD
Dasatinib—Tachycardia—Epirubicin—sarcoma	3.24e-05	0.000388	CcSEcCtD
Dasatinib—Skin disorder—Epirubicin—sarcoma	3.22e-05	0.000387	CcSEcCtD
Dasatinib—Hyperhidrosis—Epirubicin—sarcoma	3.21e-05	0.000385	CcSEcCtD
Dasatinib—Chest pain—Doxorubicin—sarcoma	3.2e-05	0.000384	CcSEcCtD
Dasatinib—Myalgia—Doxorubicin—sarcoma	3.2e-05	0.000384	CcSEcCtD
Dasatinib—Arthralgia—Doxorubicin—sarcoma	3.2e-05	0.000384	CcSEcCtD
Dasatinib—Anxiety—Doxorubicin—sarcoma	3.19e-05	0.000383	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	3.18e-05	0.000382	CcSEcCtD
Dasatinib—Discomfort—Doxorubicin—sarcoma	3.16e-05	0.00038	CcSEcCtD
Dasatinib—CYP1A2—liver—sarcoma	3.16e-05	0.000418	CbGeAlD
Dasatinib—Anorexia—Epirubicin—sarcoma	3.16e-05	0.000379	CcSEcCtD
Dasatinib—ABCB1—hematopoietic system—sarcoma	3.13e-05	0.000413	CbGeAlD
Dasatinib—CYP1A1—liver—sarcoma	3.12e-05	0.000412	CbGeAlD
Dasatinib—Hypotension—Epirubicin—sarcoma	3.1e-05	0.000372	CcSEcCtD
Dasatinib—Confusional state—Doxorubicin—sarcoma	3.09e-05	0.000371	CcSEcCtD
Dasatinib—Oedema—Doxorubicin—sarcoma	3.07e-05	0.000368	CcSEcCtD
Dasatinib—CYP3A5—liver—sarcoma	3.05e-05	0.000403	CbGeAlD
Dasatinib—Infection—Doxorubicin—sarcoma	3.05e-05	0.000366	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Epirubicin—sarcoma	3.02e-05	0.000363	CcSEcCtD
Dasatinib—Shock—Doxorubicin—sarcoma	3.02e-05	0.000362	CcSEcCtD
Dasatinib—Nervous system disorder—Doxorubicin—sarcoma	3.01e-05	0.000361	CcSEcCtD
Dasatinib—Thrombocytopenia—Doxorubicin—sarcoma	3e-05	0.000361	CcSEcCtD
Dasatinib—Insomnia—Epirubicin—sarcoma	3e-05	0.00036	CcSEcCtD
Dasatinib—Tachycardia—Doxorubicin—sarcoma	2.99e-05	0.000359	CcSEcCtD
Dasatinib—Skin disorder—Doxorubicin—sarcoma	2.98e-05	0.000358	CcSEcCtD
Dasatinib—Hyperhidrosis—Doxorubicin—sarcoma	2.97e-05	0.000356	CcSEcCtD
Dasatinib—Dyspnoea—Epirubicin—sarcoma	2.96e-05	0.000355	CcSEcCtD
Dasatinib—Somnolence—Epirubicin—sarcoma	2.95e-05	0.000354	CcSEcCtD
Dasatinib—Anorexia—Doxorubicin—sarcoma	2.92e-05	0.000351	CcSEcCtD
Dasatinib—Dyspepsia—Epirubicin—sarcoma	2.92e-05	0.00035	CcSEcCtD
Dasatinib—Decreased appetite—Epirubicin—sarcoma	2.88e-05	0.000346	CcSEcCtD
Dasatinib—Hypotension—Doxorubicin—sarcoma	2.87e-05	0.000344	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Epirubicin—sarcoma	2.86e-05	0.000344	CcSEcCtD
Dasatinib—Fatigue—Epirubicin—sarcoma	2.86e-05	0.000343	CcSEcCtD
Dasatinib—Pain—Epirubicin—sarcoma	2.84e-05	0.00034	CcSEcCtD
Dasatinib—Constipation—Epirubicin—sarcoma	2.84e-05	0.00034	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Doxorubicin—sarcoma	2.79e-05	0.000336	CcSEcCtD
Dasatinib—Insomnia—Doxorubicin—sarcoma	2.77e-05	0.000333	CcSEcCtD
Dasatinib—Dyspnoea—Doxorubicin—sarcoma	2.73e-05	0.000328	CcSEcCtD
Dasatinib—Feeling abnormal—Epirubicin—sarcoma	2.73e-05	0.000328	CcSEcCtD
Dasatinib—Somnolence—Doxorubicin—sarcoma	2.73e-05	0.000327	CcSEcCtD
Dasatinib—Gastrointestinal pain—Epirubicin—sarcoma	2.71e-05	0.000325	CcSEcCtD
Dasatinib—Dyspepsia—Doxorubicin—sarcoma	2.7e-05	0.000324	CcSEcCtD
Dasatinib—Decreased appetite—Doxorubicin—sarcoma	2.67e-05	0.00032	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Doxorubicin—sarcoma	2.65e-05	0.000318	CcSEcCtD
Dasatinib—Fatigue—Doxorubicin—sarcoma	2.64e-05	0.000318	CcSEcCtD
Dasatinib—Urticaria—Epirubicin—sarcoma	2.63e-05	0.000316	CcSEcCtD
Dasatinib—Constipation—Doxorubicin—sarcoma	2.62e-05	0.000315	CcSEcCtD
Dasatinib—Pain—Doxorubicin—sarcoma	2.62e-05	0.000315	CcSEcCtD
Dasatinib—Abdominal pain—Epirubicin—sarcoma	2.62e-05	0.000315	CcSEcCtD
Dasatinib—Body temperature increased—Epirubicin—sarcoma	2.62e-05	0.000315	CcSEcCtD
Dasatinib—Feeling abnormal—Doxorubicin—sarcoma	2.53e-05	0.000303	CcSEcCtD
Dasatinib—ABCG2—lymph node—sarcoma	2.52e-05	0.000333	CbGeAlD
Dasatinib—Gastrointestinal pain—Doxorubicin—sarcoma	2.51e-05	0.000301	CcSEcCtD
Dasatinib—Hypersensitivity—Epirubicin—sarcoma	2.44e-05	0.000293	CcSEcCtD
Dasatinib—Urticaria—Doxorubicin—sarcoma	2.44e-05	0.000293	CcSEcCtD
Dasatinib—Body temperature increased—Doxorubicin—sarcoma	2.43e-05	0.000291	CcSEcCtD
Dasatinib—Abdominal pain—Doxorubicin—sarcoma	2.43e-05	0.000291	CcSEcCtD
Dasatinib—CYP1A1—lymph node—sarcoma	2.39e-05	0.000316	CbGeAlD
Dasatinib—Asthenia—Epirubicin—sarcoma	2.38e-05	0.000286	CcSEcCtD
Dasatinib—ABCB1—uterus—sarcoma	2.36e-05	0.000312	CbGeAlD
Dasatinib—Pruritus—Epirubicin—sarcoma	2.35e-05	0.000282	CcSEcCtD
Dasatinib—CYP3A4—liver—sarcoma	2.29e-05	0.000302	CbGeAlD
Dasatinib—Diarrhoea—Epirubicin—sarcoma	2.27e-05	0.000272	CcSEcCtD
Dasatinib—Hypersensitivity—Doxorubicin—sarcoma	2.26e-05	0.000271	CcSEcCtD
Dasatinib—Asthenia—Doxorubicin—sarcoma	2.2e-05	0.000264	CcSEcCtD
Dasatinib—ABCB1—lymphoid tissue—sarcoma	2.2e-05	0.000291	CbGeAlD
Dasatinib—Dizziness—Epirubicin—sarcoma	2.19e-05	0.000263	CcSEcCtD
Dasatinib—Pruritus—Doxorubicin—sarcoma	2.17e-05	0.000261	CcSEcCtD
Dasatinib—Vomiting—Epirubicin—sarcoma	2.11e-05	0.000253	CcSEcCtD
Dasatinib—Diarrhoea—Doxorubicin—sarcoma	2.1e-05	0.000252	CcSEcCtD
Dasatinib—Rash—Epirubicin—sarcoma	2.09e-05	0.000251	CcSEcCtD
Dasatinib—Dermatitis—Epirubicin—sarcoma	2.09e-05	0.000251	CcSEcCtD
Dasatinib—Headache—Epirubicin—sarcoma	2.08e-05	0.000249	CcSEcCtD
Dasatinib—Dizziness—Doxorubicin—sarcoma	2.03e-05	0.000244	CcSEcCtD
Dasatinib—ABCB1—bone marrow—sarcoma	2e-05	0.000265	CbGeAlD
Dasatinib—Nausea—Epirubicin—sarcoma	1.97e-05	0.000236	CcSEcCtD
Dasatinib—Vomiting—Doxorubicin—sarcoma	1.95e-05	0.000234	CcSEcCtD
Dasatinib—Rash—Doxorubicin—sarcoma	1.93e-05	0.000232	CcSEcCtD
Dasatinib—Dermatitis—Doxorubicin—sarcoma	1.93e-05	0.000232	CcSEcCtD
Dasatinib—Headache—Doxorubicin—sarcoma	1.92e-05	0.000231	CcSEcCtD
Dasatinib—Nausea—Doxorubicin—sarcoma	1.82e-05	0.000219	CcSEcCtD
Dasatinib—ABCB1—testis—sarcoma	1.71e-05	0.000226	CbGeAlD
Dasatinib—ABCB1—liver—sarcoma	1.62e-05	0.000214	CbGeAlD
Dasatinib—ABCB1—lymph node—sarcoma	1.24e-05	0.000164	CbGeAlD
Dasatinib—RIPK2—Signaling Pathways—EGFR—sarcoma	1.27e-06	1.03e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—HRAS—sarcoma	1.26e-06	1.02e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—MDM2—sarcoma	1.25e-06	1.01e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—EGFR—sarcoma	1.25e-06	1.01e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CCND1—sarcoma	1.25e-06	1.01e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—JUN—sarcoma	1.25e-06	1.01e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—VEGFA—sarcoma	1.24e-06	1e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—NRAS—sarcoma	1.24e-06	1e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CTNNB1—sarcoma	1.24e-06	1e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—NRAS—sarcoma	1.24e-06	1e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—CTNNB1—sarcoma	1.23e-06	9.98e-06	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—HRAS—sarcoma	1.23e-06	9.93e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—NRAS—sarcoma	1.23e-06	9.92e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CREB1—sarcoma	1.23e-06	9.92e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—SRC—sarcoma	1.22e-06	9.9e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—NRAS—sarcoma	1.22e-06	9.89e-06	CbGpPWpGaD
Dasatinib—YES1—Immune System—HRAS—sarcoma	1.22e-06	9.86e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—SRC—sarcoma	1.22e-06	9.85e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ENO2—sarcoma	1.21e-06	9.82e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MDM2—sarcoma	1.21e-06	9.82e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL2—sarcoma	1.21e-06	9.81e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—KRAS—sarcoma	1.21e-06	9.8e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—MYC—sarcoma	1.21e-06	9.8e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CREB1—sarcoma	1.21e-06	9.8e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KDR—sarcoma	1.21e-06	9.78e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—SRC—sarcoma	1.21e-06	9.77e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—HBA1—sarcoma	1.21e-06	9.76e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—MDM2—sarcoma	1.2e-06	9.72e-06	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—KRAS—sarcoma	1.2e-06	9.69e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—MYC—sarcoma	1.19e-06	9.59e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—EGFR—sarcoma	1.18e-06	9.58e-06	CbGpPWpGaD
Dasatinib—KIT—Disease—KRAS—sarcoma	1.18e-06	9.56e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—JUN—sarcoma	1.18e-06	9.54e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—NRAS—sarcoma	1.18e-06	9.52e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—SRC—sarcoma	1.17e-06	9.49e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—NRAS—sarcoma	1.17e-06	9.47e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—CTNNB1—sarcoma	1.17e-06	9.47e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—NRAS—sarcoma	1.16e-06	9.4e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—EGFR—sarcoma	1.16e-06	9.38e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—EGFR—sarcoma	1.16e-06	9.38e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—EGFR—sarcoma	1.16e-06	9.35e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL2—sarcoma	1.15e-06	9.27e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—MYC—sarcoma	1.14e-06	9.24e-06	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—HRAS—sarcoma	1.13e-06	9.16e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—EGFR—sarcoma	1.13e-06	9.15e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—NRAS—sarcoma	1.13e-06	9.13e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—EGFR—sarcoma	1.13e-06	9.11e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—SRC—sarcoma	1.12e-06	9.06e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—KRAS—sarcoma	1.12e-06	9.05e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—EGFR—sarcoma	1.12e-06	9.04e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CCND1—sarcoma	1.12e-06	9.03e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—SRC—sarcoma	1.12e-06	9.02e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—JUN—sarcoma	1.11e-06	9.02e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KIT—sarcoma	1.11e-06	9.01e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—EGFR—sarcoma	1.11e-06	9.01e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MDM2—sarcoma	1.11e-06	8.97e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CTNNB1—sarcoma	1.11e-06	8.95e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—KRAS—sarcoma	1.1e-06	8.86e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—KRAS—sarcoma	1.1e-06	8.86e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MDM2—sarcoma	1.09e-06	8.85e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—KRAS—sarcoma	1.09e-06	8.83e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—MYC—sarcoma	1.09e-06	8.83e-06	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—MYC—sarcoma	1.09e-06	8.82e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—VEGFA—sarcoma	1.09e-06	8.82e-06	CbGpPWpGaD
Dasatinib—KIT—Immune System—HRAS—sarcoma	1.09e-06	8.8e-06	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—HRAS—sarcoma	1.09e-06	8.79e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL2—sarcoma	1.08e-06	8.77e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—CTNNB1—sarcoma	1.08e-06	8.74e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—NRAS—sarcoma	1.08e-06	8.71e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL2—sarcoma	1.07e-06	8.68e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—NRAS—sarcoma	1.07e-06	8.68e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—EGFR—sarcoma	1.07e-06	8.68e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KDR—sarcoma	1.07e-06	8.66e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MDM2—sarcoma	1.07e-06	8.66e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—KRAS—sarcoma	1.07e-06	8.65e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—EGFR—sarcoma	1.07e-06	8.63e-06	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—sarcoma	1.06e-06	8.61e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—KRAS—sarcoma	1.06e-06	8.61e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CREB1—sarcoma	1.06e-06	8.58e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—EGFR—sarcoma	1.06e-06	8.57e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—SRC—sarcoma	1.06e-06	8.56e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CCND1—sarcoma	1.06e-06	8.55e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—KRAS—sarcoma	1.06e-06	8.54e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—JUN—sarcoma	1.06e-06	8.53e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MDM2—sarcoma	1.05e-06	8.53e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—KRAS—sarcoma	1.05e-06	8.51e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—MYC—sarcoma	1.05e-06	8.51e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CTNNB1—sarcoma	1.05e-06	8.47e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—JUN—sarcoma	1.04e-06	8.45e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—CTNNB1—sarcoma	1.04e-06	8.38e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PLCG1—sarcoma	1.03e-06	8.34e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—HRAS—sarcoma	1.03e-06	8.33e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—EGFR—sarcoma	1.03e-06	8.32e-06	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—HRAS—sarcoma	1.02e-06	8.24e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—NRAS—sarcoma	1.02e-06	8.23e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MDM2—sarcoma	1.02e-06	8.21e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—KRAS—sarcoma	1.01e-06	8.2e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—KRAS—sarcoma	1.01e-06	8.15e-06	CbGpPWpGaD
Dasatinib—KIT—Disease—HRAS—sarcoma	1.01e-06	8.13e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MYC—sarcoma	1e-06	8.11e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MDM2—sarcoma	1e-06	8.1e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—KRAS—sarcoma	1e-06	8.09e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—SRC—sarcoma	1e-06	8.09e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—MYC—sarcoma	1e-06	8.09e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KIT—sarcoma	9.87e-07	7.98e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—EGFR—sarcoma	9.81e-07	7.94e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—EGFR—sarcoma	9.78e-07	7.91e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL2—sarcoma	9.77e-07	7.9e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—SRC—sarcoma	9.77e-07	7.9e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—VEGFA—sarcoma	9.74e-07	7.88e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—sarcoma	9.74e-07	7.88e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—KRAS—sarcoma	9.72e-07	7.86e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—NRAS—sarcoma	9.62e-07	7.78e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—CTNNB1—sarcoma	9.57e-07	7.74e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL2—sarcoma	9.57e-07	7.74e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CCND1—sarcoma	9.53e-07	7.7e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—HRAS—sarcoma	9.51e-07	7.69e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—JUN—sarcoma	9.51e-07	7.69e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—SRC—sarcoma	9.47e-07	7.65e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CTNNB1—sarcoma	9.43e-07	7.63e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL2—sarcoma	9.42e-07	7.62e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—NRAS—sarcoma	9.4e-07	7.6e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CREB1—sarcoma	9.39e-07	7.6e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—sarcoma	9.39e-07	7.59e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ENO2—sarcoma	9.38e-07	7.58e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CCND1—sarcoma	9.33e-07	7.54e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HBA1—sarcoma	9.32e-07	7.53e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—HRAS—sarcoma	9.31e-07	7.53e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—HRAS—sarcoma	9.31e-07	7.53e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—JUN—sarcoma	9.31e-07	7.53e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—HRAS—sarcoma	9.28e-07	7.51e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—EGFR—sarcoma	9.28e-07	7.5e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—KRAS—sarcoma	9.27e-07	7.5e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—KRAS—sarcoma	9.24e-07	7.47e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CTNNB1—sarcoma	9.24e-07	7.47e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—VEGFA—sarcoma	9.22e-07	7.46e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CCND1—sarcoma	9.18e-07	7.43e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—JUN—sarcoma	9.16e-07	7.41e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—NRAS—sarcoma	9.11e-07	7.36e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CTNNB1—sarcoma	9.09e-07	7.35e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—HRAS—sarcoma	9.09e-07	7.35e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL2—sarcoma	9.07e-07	7.34e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—HRAS—sarcoma	9.05e-07	7.32e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—NRAS—sarcoma	9.02e-07	7.29e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—HRAS—sarcoma	8.98e-07	7.26e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MYC—sarcoma	8.96e-07	7.25e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL2—sarcoma	8.95e-07	7.24e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—HRAS—sarcoma	8.95e-07	7.24e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CCND1—sarcoma	8.84e-07	7.15e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—JUN—sarcoma	8.82e-07	7.14e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MDM2—sarcoma	8.78e-07	7.1e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EGFR—sarcoma	8.76e-07	7.09e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—KRAS—sarcoma	8.76e-07	7.09e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—MYC—sarcoma	8.76e-07	7.08e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CTNNB1—sarcoma	8.76e-07	7.08e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCND1—sarcoma	8.73e-07	7.06e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—JUN—sarcoma	8.71e-07	7.04e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CTNNB1—sarcoma	8.64e-07	6.99e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—HRAS—sarcoma	8.62e-07	6.97e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—HRAS—sarcoma	8.57e-07	6.93e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—EGFR—sarcoma	8.57e-07	6.93e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—SRC—sarcoma	8.53e-07	6.9e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HRAS—sarcoma	8.51e-07	6.88e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MYC—sarcoma	8.48e-07	6.86e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—SRC—sarcoma	8.35e-07	6.75e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—NRAS—sarcoma	8.32e-07	6.73e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—sarcoma	8.31e-07	6.72e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—sarcoma	8.3e-07	6.71e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KRAS—sarcoma	8.28e-07	6.7e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—sarcoma	8.26e-07	6.68e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—sarcoma	8.24e-07	6.66e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—SRC—sarcoma	8.22e-07	6.65e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—sarcoma	8.21e-07	6.64e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NRAS—sarcoma	8.2e-07	6.63e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—sarcoma	8.13e-07	6.58e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—sarcoma	8.09e-07	6.54e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NRAS—sarcoma	8.03e-07	6.5e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—sarcoma	8.01e-07	6.47e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PLCG1—sarcoma	7.96e-07	6.43e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—SRC—sarcoma	7.92e-07	6.4e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NRAS—sarcoma	7.91e-07	6.39e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—sarcoma	7.88e-07	6.37e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—sarcoma	7.85e-07	6.35e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL2—sarcoma	7.84e-07	6.34e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—sarcoma	7.84e-07	6.34e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—SRC—sarcoma	7.81e-07	6.32e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MDM2—sarcoma	7.77e-07	6.28e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—sarcoma	7.76e-07	6.27e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—sarcoma	7.75e-07	6.27e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—sarcoma	7.71e-07	6.23e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—sarcoma	7.65e-07	6.18e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—sarcoma	7.64e-07	6.18e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—JUN—sarcoma	7.63e-07	6.17e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NRAS—sarcoma	7.61e-07	6.16e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—sarcoma	7.61e-07	6.15e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—sarcoma	7.58e-07	6.13e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CTNNB1—sarcoma	7.57e-07	6.12e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NRAS—sarcoma	7.52e-07	6.08e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—sarcoma	7.48e-07	6.05e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—sarcoma	7.47e-07	6.04e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—sarcoma	7.45e-07	6.02e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—sarcoma	7.37e-07	5.96e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—sarcoma	7.36e-07	5.95e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—sarcoma	7.32e-07	5.92e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—sarcoma	7.2e-07	5.83e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—sarcoma	7.16e-07	5.79e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—sarcoma	7.09e-07	5.74e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—sarcoma	7.06e-07	5.71e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—sarcoma	7.04e-07	5.69e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—sarcoma	7e-07	5.66e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—sarcoma	6.97e-07	5.63e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL2—sarcoma	6.94e-07	5.61e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—sarcoma	6.94e-07	5.61e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—sarcoma	6.91e-07	5.59e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—sarcoma	6.88e-07	5.56e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—sarcoma	6.85e-07	5.54e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SRC—sarcoma	6.84e-07	5.53e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—sarcoma	6.81e-07	5.5e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—sarcoma	6.77e-07	5.47e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—JUN—sarcoma	6.75e-07	5.46e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CTNNB1—sarcoma	6.7e-07	5.42e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—sarcoma	6.67e-07	5.39e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—sarcoma	6.66e-07	5.39e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—sarcoma	6.6e-07	5.33e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NRAS—sarcoma	6.58e-07	5.32e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—sarcoma	6.55e-07	5.3e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—sarcoma	6.47e-07	5.23e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—sarcoma	6.28e-07	5.08e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—sarcoma	6.14e-07	4.97e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—sarcoma	6.13e-07	4.96e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—sarcoma	6.09e-07	4.92e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—sarcoma	6.05e-07	4.89e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—sarcoma	6e-07	4.85e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—sarcoma	6e-07	4.85e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—sarcoma	5.9e-07	4.77e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—sarcoma	5.88e-07	4.75e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NRAS—sarcoma	5.83e-07	4.71e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—sarcoma	5.82e-07	4.71e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—sarcoma	5.79e-07	4.68e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—sarcoma	5.75e-07	4.65e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—sarcoma	5.67e-07	4.58e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—sarcoma	5.57e-07	4.5e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—sarcoma	5.5e-07	4.45e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—sarcoma	5.43e-07	4.39e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—sarcoma	5.31e-07	4.29e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—sarcoma	5.04e-07	4.07e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—sarcoma	5.02e-07	4.06e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—sarcoma	4.82e-07	3.9e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—sarcoma	4.46e-07	3.61e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—sarcoma	4.26e-07	3.45e-06	CbGpPWpGaD
